From T-cell sensitization to molecular–intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection
Clinical Microbiology Reviews · 11.06.2026 · 39 (2)
DOI: 10.1128/cmr.00258-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 11.06.2026. Verfasst von Ruizi Ni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Tuberculosis, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Latent Tuberculosis, T-Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 312 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
One quarter of the world’s population carries latent tuberculosis infection (LTBI), an invisible reservoir that must be drained to end the global tuberculosis (TB) epidemic. This review charts the evolution of LTBI diagnosis from the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) to a new molecular–intelligent paradigm. At the clinical level, we propose a CD4/age-stratified, resource-matched decision framework that delivers actionable screening and sequencing strategies for people living with HIV, children, the immunosuppressed, and pregnant women. At the biomarker level, we integrate host-derived analytes (CXCL1, CCL8, IP-10, CD38 + CD27⁻ T cells, and Fc-glycosylated antibodies) with pathogen-derived antigens (dormancy survival regulator [DosR], resuscitation-promoting factor [Rpf], heparin-binding hemagglutinin [HBHA], and PE/PPE) to create a three-tier index: single-analyte triage, multi-analyte confirmation, and dynamic treatment monitoring. At the technology level, we benchmark multi-omics-plus-AI models, single-molecule Simoa arrays, and microfluidic point-of-care testing (POCT) platforms for sensitivity, accessibility, and cost. High-quality cross-population validation, standardized thresholds, and resource-tiered deployment remain the principal translational bottlenecks. We call for integrated programs that combine key-population multicenter cohorts, explainable AI, and ASSURED criteria to propel LTBI management from the T-cell-sensitization era into the molecular–intelligent age. Achieving this vision within 5 years is technically feasible and will accelerate global elimination targets by enabling precision preventive therapy at an unprecedented scale.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Tuberculosis, Chinese PLA General Hospital, Beijing, China.
- Graduate School, Hebei North University, Zhangjiakou, Hebei, China.
- Biotechnology and Biosciences Department, University of Milano-Bicocca, Milan, Italy.
ORCID-Profile: Antonia Bruno, Lingxia Zhang, Wenping Gong
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Ni, R., Liu, Y., Armanni, A., Ghisleni, G., Fumagalli, S., An, Y., Li, Y., Zhuang, L., Ling, Y., Li, L., Ye, Z., Bruno, A., Zhang, L., & Gong, W. (2026). From T-cell sensitization to molecular–intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection. Clinical Microbiology Reviews, 39(2). https://doi.org/10.1128/cmr.00258-25
Vancouver
Ni R, Liu Y, Armanni A, Ghisleni G, Fumagalli S, An Y, et al. From T-cell sensitization to molecular–intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection. Clinical Microbiology Reviews. 2026;39(2). doi:10.1128/cmr.00258-25
BibTeX
@article{Ni2026,
author = {Ni, Ruizi and Liu, Yanhua and Armanni, Alice and Ghisleni, Giulia and Fumagalli, Sara and An, Yajing and Li, Yufeng and Zhuang, Li and Ling, Yang and Li, Linsheng and Ye, Zhaoyang and Bruno, Antonia and Zhang, Lingxia and Gong, Wenping},
title = {From T-cell sensitization to molecular–intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection},
journal = {Clinical Microbiology Reviews},
year = {2026},
volume = {39},
number = {2},
doi = {10.1128/cmr.00258-25}
}
EUVIMED